Drugs in MeSH Category Narcotic Antagonists

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Kaleo Inc	EVZIO	naloxone hydrochloride	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	205787-001	Apr 3, 2014		DISCN	Yes	No	8,021,344		Y
Hikma	KLOXXADO	naloxone hydrochloride	SPRAY;NASAL	212045-001	Apr 29, 2021		RX	Yes	Yes	11,135,155		Y
Braeburn	BRIXADI	buprenorphine	SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS	210136-003	May 23, 2023		RX	Yes	Yes	11,135,215		Y

Narcotic Antagonists Market Dynamics and Patent Landscape

Last updated: August 1, 2026

The narcotic antagonist market is divided between emergency overdose reversal, opioid-use-disorder treatment, and opioid-induced constipation. Naloxone has the largest public-health and unit-volume market, while extended-release naltrexone and prescription peripherally acting mu-opioid receptor antagonists generate higher value per patient. Core composition-of-matter patents have expired for most products. Remaining protection is concentrated in nasal-delivery systems, injectable depot formulations, PEGylated molecules, solid-state forms, manufacturing processes, and method-of-use patents.

Which drugs are included in the NLM MeSH Narcotic Antagonists class?

The MeSH category includes opioid receptor antagonists and related compounds that block or reduce opioid activity. Commercially important products fall into four groups.

Drug	Principal products	Main use	Route
Naloxone	Narcan, generic naloxone	Opioid overdose reversal	Intranasal, injection
Naltrexone	ReVia, generic naltrexone, Vivitrol	Alcohol-use disorder and opioid-use disorder	Oral, extended-release injection
Nalmefene	Zurnai, generic injection; Opvee nasal spray	Opioid overdose reversal	Injection, intranasal
Methylnaltrexone	Relistor	Opioid-induced constipation	Oral, subcutaneous
Naloxegol	Movantik	Opioid-induced constipation	Oral
Naldemedine	Symproic	Opioid-induced constipation	Oral
Alvimopan	Entereg	Postoperative ileus	Oral, restricted hospital use

Naloxegol, naldemedine, and methylnaltrexone retain peripheral opioid activity while limiting central nervous system penetration. Alvimopan is also peripherally acting and is used under a risk-management program because of cardiovascular concerns identified during development. FDA labels define the approved indications, dosing, and safety restrictions for each product.[1-7]

How large is the narcotic antagonist market?

Market value is concentrated in naloxone, branded long-acting naltrexone, and prescription constipation products. Unit demand is highest for naloxone because products are distributed through emergency medical systems, pharmacies, public-health programs, schools, first responders, and community organizations.

Naloxone has the broadest demand base

Naloxone demand is driven by opioid overdose mortality, public procurement, standing pharmacy orders, harm-reduction programs, and expanded access policies. FDA approved Narcan 4 mg nasal spray for nonprescription use in 2023, increasing the addressable retail market.[8] FDA later approved additional nonprescription naloxone products and maintained prescription and generic channels.

Commercial dynamics differ from conventional chronic medicines:

• Public-sector purchasing can determine volume and price.
• Institutional buyers often favor unit-dose nasal devices.
• Generic injectable naloxone remains important in hospitals and ambulances.
• Brand value depends on device usability, shelf life, supply reliability, and public procurement contracts.
• OTC conversion expands distribution but can increase price competition.

Naltrexone has a split market

Oral naltrexone is generic and low-cost. Vivitrol, an extended-release naltrexone microsphere injection marketed by Alkermes, competes on adherence and monthly administration rather than chemical novelty. The product is used for alcohol-use disorder and prevention of relapse to opioid dependence after detoxification.[2]

The commercial risks are different by formulation:

• Oral tablets face mature generic competition.
• Vivitrol faces substitution by oral naltrexone, buprenorphine products, methadone, and behavioral-treatment programs.
• The injectable formulation has greater manufacturing complexity and a higher treatment cost.
• Payer restrictions and initiation logistics affect utilization.

Opioid-induced constipation products compete in a narrower market

Relistor, Movantik, and Symproic address opioid-induced constipation in patients receiving chronic opioid therapy. Their commercial performance depends on opioid prescribing, reimbursement, formulary position, and differentiation among peripheral opioid receptor antagonists.

Product	Active ingredient	Company history	Commercial position
Relistor	Methylnaltrexone	Salix/Valeant, now Bausch Health	Injectable and oral options; earlier market entry
Movantik	Naloxegol	AstraZeneca, later commercial partners	Oral once-daily treatment
Symproic	Naldemedine	Shionogi	Oral treatment with differentiated clinical positioning
Entereg	Alvimopan	Merck	Hospital product for postoperative ileus

What patents protect narcotic antagonist drugs?

Patent protection varies materially by active ingredient and dosage form. Most first-generation compounds are off-patent. The strongest surviving estates generally protect delivery technology, long-acting formulations, chemical modifications, or specific clinical uses.

Naloxone patent landscape

Naloxone hydrochloride is an established active ingredient with expired basic compound protection. Patent value has shifted to:

• Intranasal delivery devices.
• Concentrated aqueous formulations.
• Spray performance and dose uniformity.
• Container-closure systems.
• Stability and shelf-life improvements.
• Low-cost manufacturing and packaging.
• OTC labeling and human-factors data.

Narcan nasal spray was approved under NDA 208411. Teva received FDA approval for a generic naloxone hydrochloride nasal spray in 2021, creating direct abbreviated new drug application competition.[9] FDA’s OTC approval of Narcan reduced the practical importance of prescription-only distribution but did not eliminate device, formulation, or brand-market barriers.

The principal patent risk for new entrants is less likely to come from the naloxone molecule itself than from device design, formulation claims, and regulatory requirements for a comparable nasal product.

Naltrexone and Vivitrol patents

Oral naltrexone is a mature generic drug. Vivitrol’s protection has historically focused on extended-release injectable microspheres, polymer composition, particle characteristics, release profiles, and manufacturing methods rather than the naltrexone molecule.

Relevant patent issues include:

• Polymer-encapsulated naltrexone particles.
• Sustained-release injectable compositions.
• Particle-size distribution.
• In vitro and in vivo release profiles.
• Reconstitution and administration methods.
• Treatment methods using monthly naltrexone injections.

The Vivitrol estate has been subject to patent disputes and ANDA challenges. In such cases, the commercial outcome depends on which Orange Book patents are listed, the scope of asserted claims, regulatory exclusivity, and whether a court grants a launch restriction or the parties settle. Alkermes’ manufacturing process and experience with complex injectable microspheres also create barriers independent of formal patent expiry.[10]

Methylnaltrexone patents

Relistor protection has covered the methylnaltrexone compound, pharmaceutical compositions, dosing regimens, and treatment of opioid-induced constipation. The basic active ingredient is mature, but commercial protection has extended through:

• Oral tablets.
• Subcutaneous injection.
• Specific dose ranges.
• Use in advanced illness or chronic noncancer pain.
• Formulation and manufacturing claims.

The transition from injectable to oral dosage forms increased the relevance of formulation and method-of-use patents. Bausch Health has faced generic pressure as the principal patent barriers have expired or narrowed.

Naloxegol patents

Naloxegol is a PEGylated derivative of naloxol designed to reduce central opioid antagonism. Patent protection has covered the modified molecule, composition, preparation, and use in opioid-induced constipation.

The patent estate has included U.S. composition-of-matter and formulation claims associated with AstraZeneca’s development program. The main barriers to generic entry have been:

• Complexity of the PEGylated active ingredient.
• Control of molecular substitution and impurity profiles.
• Bioequivalence for a modified-release oral product.
• Manufacturing reproducibility.
• Orange Book-listed formulation and method patents.

Naloxegol’s chemical modification makes process chemistry and analytical characterization more important than for conventional oral naltrexone or naloxone.

Naldemedine patents

Symproic is based on naldemedine, a derivative of naltrexone designed for peripheral activity. Shionogi’s patent program has addressed:

• The naldemedine molecule.
• Pharmaceutical compositions.
• Treatment of opioid-induced constipation.
• Dosing in patients receiving chronic opioid therapy.
• Solid-state and formulation characteristics.

The molecule and its manufacturing route are more important barriers than device protection. Generic applicants must demonstrate pharmaceutical equivalence and bioequivalence while addressing listed patents through paragraph IV certifications or a section viii statement, depending on the proposed labeling.[11]

Alvimopan patents

Entereg has a mature patent position centered on alvimopan chemistry, oral formulations, and postoperative ileus treatment. The product is distributed through a restricted hospital program, which limits market size and affects generic commercialization.

The main competitive constraints are:

• Restricted-use distribution.
• Hospital formulary adoption.
• Limited indication.
• Complex safety and risk-management requirements.
• Established perioperative treatment protocols.

When do major narcotic antagonists lose exclusivity?

Exclusivity depends on the patent family, approved formulation, listed patents, pediatric extensions, regulatory exclusivity, and litigation. Basic compound patents have expired for naloxone, naltrexone, and methylnaltrexone. The practical loss of exclusivity has occurred at different times by product and dosage form.

Product	Core exclusivity position	Main remaining or historical barriers
Generic injectable naloxone	Mature generic market	Device, packaging, procurement contracts
Narcan nasal spray	Brand and device differentiation	Nasal formulation, device, OTC market access
Oral naltrexone	Generic	None material at the active-ingredient level
Vivitrol	Complex injectable formulation	Microsphere formulation, manufacturing, listed patents
Relistor	Mature branded/generic pressure	Oral formulation, dosing, use patents
Movantik	PEGylated molecule and oral formulation	Chemical process, formulation, listed patents
Symproic	Derivative compound and use patents	Composition, formulation, method patents
Entereg	Hospital-restricted product	Use patents, distribution program, limited market

The FDA Orange Book is the controlling public source for approved drug products and listed patents. Orange Book entries can change as patents expire, are delisted, or are affected by litigation.[12]

Which companies are challenging narcotic antagonist patents?

Generic challenges have focused on products with meaningful price differentials and sufficiently large patient populations.

Naloxone challengers

Teva’s approval of generic naloxone nasal spray established an ANDA pathway for a noninjectable product. Other manufacturers compete in injectable naloxone, including generic hospital suppliers. The main competitive issue is supply capacity rather than active-ingredient patent protection.

Vivitrol challengers

Vivitrol is exposed to ANDA risk from companies capable of developing complex microsphere injections. Generic entry requires more than matching the naltrexone dose. Applicants must reproduce release characteristics, particle attributes, suspension behavior, and manufacturing controls. This creates a higher technical barrier than for oral tablets.

Opioid-induced constipation challengers

Movantik, Symproic, and Relistor face differentiated generic risks:

• Movantik requires control of a PEGylated active ingredient and oral product performance.
• Symproic requires synthesis and characterization of a naltrexone-derived compound.
• Relistor has both oral and injectable formulations, creating separate development and regulatory paths.

Patent litigation is likely to center on ANDA paragraph IV notices, Orange Book-listed formulation claims, and whether generic labels induce infringement of method-of-use patents.

What is the FDA and Orange Book status of these products?

FDA regulatory status differs by product type.

Regulatory issue	Market effect
NDA approval	Establishes the reference product for ANDA competition
Orange Book listing	Identifies patents that may trigger a 30-month stay after a paragraph IV notice
Paragraph IV certification	Creates potential patent litigation before generic approval
Section viii statement	Allows approval for nonpatented uses if labeling is carved out
OTC switch	Expands access and changes channel economics
REMS or restricted distribution	Raises operational barriers for competitors
Complex dosage form designation	Increases development and bioequivalence difficulty

Narcan’s OTC approval is the most consequential recent regulatory change in the class. It expands consumer access while exposing the brand to substitution by future OTC and prescription nasal products.[8]

Vivitrol and Entereg have additional commercial constraints because administration, distribution, or patient selection affects use. For opioid-induced constipation drugs, FDA labeling limits the relevant patient populations and determines which method-of-use claims can support a generic carve-out.

How strong is the patent estate for narcotic antagonists?

Patent strength is highest where the product combines a differentiated molecule with a difficult dosage form.

Product	Composition strength	Formulation strength	Manufacturing barrier	Overall protection
Injectable naloxone	Low	Low to moderate	Low	Low
Nasal naloxone	Low	Moderate	Moderate	Moderate
Oral naltrexone	Low	Low	Low	Low
Vivitrol	Low to moderate	High	High	Moderate to high
Relistor	Moderate historically	Moderate	Moderate	Moderate
Movantik	Moderate to high	Moderate	High	Moderate to high
Symproic	Moderate to high	Moderate	Moderate to high	Moderate to high
Entereg	Moderate historically	Low to moderate	Moderate	Low to moderate

Patent strength should be assessed claim by claim. A broad composition claim can block substitution across dosage forms, while a narrow method-of-use claim may be avoidable through label carving. For complex injectables, manufacturing know-how may remain commercially important after the last enforceable patent expires.

What generic launch scenarios exist?

Immediate or low-barrier launch

Injectable naloxone and oral naltrexone have the lowest entry barriers. Multiple manufacturers can compete on price, supply, and contracting. Revenue erosion can be rapid after several ANDA approvals.

Delayed launch after paragraph IV litigation

Vivitrol, Movantik, Symproic, and selected Relistor formulations are more likely to produce delayed generic entry. Outcomes include:

1. Patent invalidation or noninfringement followed by an at-risk launch.
2. Settlement with a specified licensed-entry date.
3. Approval with a label carve-out.
4. Launch after patent expiry.
5. Commercial delay caused by manufacturing validation even after regulatory approval.

Authorized generic or licensed entry

A branded company may use an authorized generic, license a generic manufacturer, or settle with a defined entry date. This can preserve some supply-chain control while reducing the risk of an uncontrolled market launch.

What licensing deals affect the class?

Commercial rights have moved across companies as products matured. Naloxone has a broad network of public-sector, nonprofit, pharmacy, and distribution relationships. Vivitrol remains associated with Alkermes. Relistor has changed hands through corporate transactions involving Salix and Bausch Health. Movantik has been subject to commercialization arrangements after AstraZeneca’s initial development and launch activities. Symproic remains associated with Shionogi.

Licensing value is highest for:

• Nasal-delivery platforms.
• Long-acting injectable technology.
• PEGylated opioid derivatives.
• Hospital distribution infrastructure.
• Government procurement access.
• Manufacturing capacity for complex dosage forms.

What patent litigation and settlement risks affect narcotic antagonists?

The main litigation triggers are ANDA paragraph IV certifications and disputes over:

• Whether a listed patent properly covers the proposed product.
• Whether a generic label induces infringement.
• Whether formulation claims are valid and enabled.
• Whether the patent owner can enforce claims against a process used outside the United States.
• Whether a settlement delays entry beyond the true patent term.
• Whether a generic can launch at risk after a favorable court ruling.

Settlement agreements can create substantial differences between the date of FDA approval and the date of commercial launch. For investors and licensing teams, the relevant date is the contractual launch date, not merely the expiration date printed in a patent database.

How does the narcotic antagonist market compare with competing opioid treatments?

Naloxone competes indirectly with overdose-prevention systems, emergency response, and harm-reduction programs rather than with another chronic drug. Naltrexone competes with buprenorphine and methadone for opioid-use-disorder treatment, while Vivitrol’s monthly dosing competes with long-acting buprenorphine injections and daily oral therapies.

For opioid-induced constipation, peripheral antagonists compete with laxatives, stool softeners, secretagogues, and nonpharmacologic treatment. Their value is highest when conventional laxatives fail and opioid therapy must continue.

What geographic coverage and manufacturing barriers matter?

United States protection is the most commercially significant because FDA approval, Orange Book listing, and ANDA litigation determine launch timing. European and other jurisdictions may have different patent terms, supplementary protection certificates, data exclusivity periods, and litigation outcomes.

Manufacturing barriers differ sharply:

• Naloxone injection is relatively scalable.
• Nasal sprays require reliable device assembly and dose uniformity.
• Vivitrol requires controlled microsphere production and sterile injectable manufacturing.
• Naloxegol requires reproducible PEGylation and impurity control.
• Naldemedine requires consistent synthesis of a modified opioid antagonist.
• Relistor requires separate controls for oral and injectable products.

The greatest post-patent risk is therefore concentrated in complex products where regulatory approval does not guarantee commercial supply.

What revenue exposure exists for originators?

Revenue exposure is greatest where a product has:

• High annual treatment cost.
• Limited therapeutic substitutes.
• A complex formulation.
• Few qualified manufacturers.
• Strong institutional or specialty-pharmacy distribution.
• A narrow but defensible patient population.

Vivitrol, Symproic, Movantik, and selected Relistor formulations have greater revenue sensitivity to a single generic entrant than injectable naloxone, where the market is already largely generic and procurement-driven. Narcan’s OTC status creates a different exposure: brand sales can grow through expanded access, but retail substitution and lower-cost competitors can compress price.

Key Takeaways

• Naloxone has the largest public-health market and the weakest molecule-level patent position.
• Narcan’s principal competitive defenses are nasal-device design, brand recognition, procurement access, and regulatory positioning.
• Oral naltrexone is a mature generic market; Vivitrol remains protected by complex microsphere formulation and manufacturing requirements.
• Relistor, Movantik, and Symproic rely on derivative chemistry, formulation, dosing, and method-of-use patents.
• Paragraph IV litigation and settlement dates can materially change the commercial launch timetable.
• Manufacturing capability is a major barrier for Vivitrol and chemically modified products even after core patents expire.
• Orange Book listings, FDA labeling, and section viii carve-outs determine the practical scope of generic competition.
• The class has limited biosimilar risk because these products are small-molecule drugs, not biologics. Competition is primarily generic, authorized-generic, or device-based.

FAQs

Are narcotic antagonists biologics subject to biosimilar competition?

No. The principal products in this MeSH class are small molecules. Competition proceeds through ANDAs, 505(b)(2) applications, generic injectable products, and device-specific regulatory pathways rather than biosimilar applications.

Does naloxone have composition-of-matter patent protection?

The basic naloxone compound is off patent. Current commercial protection is concentrated in nasal formulations, delivery devices, packaging, stability, and related manufacturing claims.

Is Vivitrol protected by a patent on naltrexone itself?

No. The commercial protection historically associated with Vivitrol centers on extended-release microsphere formulations, particle characteristics, release performance, manufacturing, and treatment methods.

Which opioid antagonist has the highest manufacturing barrier?

Vivitrol generally has the highest formulation and manufacturing barrier because it is a sterile long-acting microsphere injection. Naloxegol and naldemedine also require specialized chemical manufacturing and analytical controls.

Can a generic launch before all patents expire?

Yes, in some circumstances. A generic may prevail in paragraph IV litigation, enter under a settlement agreement, use a section viii label carve-out, or launch at risk after regulatory approval. The outcome depends on the specific Orange Book patents and proposed labeling.

References

1. U.S. Food and Drug Administration. (2024). Naltrexone hydrochloride prescribing information.
2. U.S. Food and Drug Administration. (2024). Vivitrol prescribing information. Alkermes, Inc.
3. U.S. Food and Drug Administration. (2024). Relistor prescribing information.
4. U.S. Food and Drug Administration. (2024). Movantik prescribing information.
5. U.S. Food and Drug Administration. (2024). Symproic prescribing information. Shionogi Inc.
6. U.S. Food and Drug Administration. (2024). Entereg prescribing information.
7. U.S. Food and Drug Administration. (2024). Naloxone hydrochloride injection prescribing information.
8. U.S. Food and Drug Administration. (2023). FDA approves first over-the-counter naloxone nasal spray.
9. U.S. Food and Drug Administration. (2021). FDA approves first generic naloxone hydrochloride nasal spray.
10. Alkermes plc. (2024). Annual report for fiscal year 2023.
11. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations.
12. U.S. Food and Drug Administration. (2024). Approved drug product list and patent information resources.